Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders

Wilbur P Trey Williams, Dewey E. McLin, Marlene A. Dressman, David Neubauer

Research output: Contribution to journalReview article

Abstract

Circadian rhythm sleep-wake disorders (CRSWDs) are characterized by persistent or recurrent patterns of sleep disturbance related primarily to alterations of the circadian rhythm system or the misalignment between the endogenous circadian rhythm and exogenous factors that affect the timing or duration of sleep. These disorders collectively represent a significant unmet medical need, with a total prevalence in the millions, a substantial negative impact on quality of life, and a lack of studied treatments for most of these disorders. Activation of the endogenous melatonin receptors appears to play an important role in setting the circadian clock in the suprachiasmatic nucleus of the hypothalamus. Therefore, melatonin agonists, which may be able to shift and/or stabilize the circadian phase, have been identified as potential therapeutic candidates for the treatment of CRSWDs. Currently, only one melatonin receptor agonist, tasimelteon, is approved for the treatment of a CRSWD: non–24-hour sleep-wake disorder (or non-24). However, three additional commercially available melatonin receptor agonists—agomelatine, prolonged-release melatonin, and ramelteon—have been investigated for potential use for treatment of CRSWDs. Data indicate that these melatonin receptor agonists have distinct pharmacologic profiles that may help clarify their clinical use in CRSWDs. We review the pharmacokinetic and pharmacodynamic properties of these melatonin agonists and summarize their efficacy profiles when used for the treatment of CRSWDs. Further studies are needed to determine the therapeutic potential of these melatonin agonists for most CRSWDs.

Original languageEnglish (US)
Pages (from-to)1028-1041
Number of pages14
JournalPharmacotherapy
Volume36
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Circadian Rhythm Sleep Disorders
Melatonin
Melatonin Receptors
Therapeutics
Circadian Rhythm
Sleep
Circadian Clocks
Suprachiasmatic Nucleus
Sleep Wake Disorders
Hypothalamus
Pharmacokinetics
Quality of Life

Keywords

  • circadian rhythm
  • drug effects
  • melatonin agonists
  • sleep drug effects

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders. / Williams, Wilbur P Trey; McLin, Dewey E.; Dressman, Marlene A.; Neubauer, David.

In: Pharmacotherapy, Vol. 36, No. 9, 01.09.2016, p. 1028-1041.

Research output: Contribution to journalReview article

Williams, Wilbur P Trey ; McLin, Dewey E. ; Dressman, Marlene A. ; Neubauer, David. / Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders. In: Pharmacotherapy. 2016 ; Vol. 36, No. 9. pp. 1028-1041.
@article{77d1d3326d9b4b49ab9170bad9ec8ca6,
title = "Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders",
abstract = "Circadian rhythm sleep-wake disorders (CRSWDs) are characterized by persistent or recurrent patterns of sleep disturbance related primarily to alterations of the circadian rhythm system or the misalignment between the endogenous circadian rhythm and exogenous factors that affect the timing or duration of sleep. These disorders collectively represent a significant unmet medical need, with a total prevalence in the millions, a substantial negative impact on quality of life, and a lack of studied treatments for most of these disorders. Activation of the endogenous melatonin receptors appears to play an important role in setting the circadian clock in the suprachiasmatic nucleus of the hypothalamus. Therefore, melatonin agonists, which may be able to shift and/or stabilize the circadian phase, have been identified as potential therapeutic candidates for the treatment of CRSWDs. Currently, only one melatonin receptor agonist, tasimelteon, is approved for the treatment of a CRSWD: non–24-hour sleep-wake disorder (or non-24). However, three additional commercially available melatonin receptor agonists—agomelatine, prolonged-release melatonin, and ramelteon—have been investigated for potential use for treatment of CRSWDs. Data indicate that these melatonin receptor agonists have distinct pharmacologic profiles that may help clarify their clinical use in CRSWDs. We review the pharmacokinetic and pharmacodynamic properties of these melatonin agonists and summarize their efficacy profiles when used for the treatment of CRSWDs. Further studies are needed to determine the therapeutic potential of these melatonin agonists for most CRSWDs.",
keywords = "circadian rhythm, drug effects, melatonin agonists, sleep drug effects",
author = "Williams, {Wilbur P Trey} and McLin, {Dewey E.} and Dressman, {Marlene A.} and David Neubauer",
year = "2016",
month = "9",
day = "1",
doi = "10.1002/phar.1822",
language = "English (US)",
volume = "36",
pages = "1028--1041",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders

AU - Williams, Wilbur P Trey

AU - McLin, Dewey E.

AU - Dressman, Marlene A.

AU - Neubauer, David

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Circadian rhythm sleep-wake disorders (CRSWDs) are characterized by persistent or recurrent patterns of sleep disturbance related primarily to alterations of the circadian rhythm system or the misalignment between the endogenous circadian rhythm and exogenous factors that affect the timing or duration of sleep. These disorders collectively represent a significant unmet medical need, with a total prevalence in the millions, a substantial negative impact on quality of life, and a lack of studied treatments for most of these disorders. Activation of the endogenous melatonin receptors appears to play an important role in setting the circadian clock in the suprachiasmatic nucleus of the hypothalamus. Therefore, melatonin agonists, which may be able to shift and/or stabilize the circadian phase, have been identified as potential therapeutic candidates for the treatment of CRSWDs. Currently, only one melatonin receptor agonist, tasimelteon, is approved for the treatment of a CRSWD: non–24-hour sleep-wake disorder (or non-24). However, three additional commercially available melatonin receptor agonists—agomelatine, prolonged-release melatonin, and ramelteon—have been investigated for potential use for treatment of CRSWDs. Data indicate that these melatonin receptor agonists have distinct pharmacologic profiles that may help clarify their clinical use in CRSWDs. We review the pharmacokinetic and pharmacodynamic properties of these melatonin agonists and summarize their efficacy profiles when used for the treatment of CRSWDs. Further studies are needed to determine the therapeutic potential of these melatonin agonists for most CRSWDs.

AB - Circadian rhythm sleep-wake disorders (CRSWDs) are characterized by persistent or recurrent patterns of sleep disturbance related primarily to alterations of the circadian rhythm system or the misalignment between the endogenous circadian rhythm and exogenous factors that affect the timing or duration of sleep. These disorders collectively represent a significant unmet medical need, with a total prevalence in the millions, a substantial negative impact on quality of life, and a lack of studied treatments for most of these disorders. Activation of the endogenous melatonin receptors appears to play an important role in setting the circadian clock in the suprachiasmatic nucleus of the hypothalamus. Therefore, melatonin agonists, which may be able to shift and/or stabilize the circadian phase, have been identified as potential therapeutic candidates for the treatment of CRSWDs. Currently, only one melatonin receptor agonist, tasimelteon, is approved for the treatment of a CRSWD: non–24-hour sleep-wake disorder (or non-24). However, three additional commercially available melatonin receptor agonists—agomelatine, prolonged-release melatonin, and ramelteon—have been investigated for potential use for treatment of CRSWDs. Data indicate that these melatonin receptor agonists have distinct pharmacologic profiles that may help clarify their clinical use in CRSWDs. We review the pharmacokinetic and pharmacodynamic properties of these melatonin agonists and summarize their efficacy profiles when used for the treatment of CRSWDs. Further studies are needed to determine the therapeutic potential of these melatonin agonists for most CRSWDs.

KW - circadian rhythm

KW - drug effects

KW - melatonin agonists

KW - sleep drug effects

UR - http://www.scopus.com/inward/record.url?scp=84990250872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990250872&partnerID=8YFLogxK

U2 - 10.1002/phar.1822

DO - 10.1002/phar.1822

M3 - Review article

VL - 36

SP - 1028

EP - 1041

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 9

ER -